Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQT Study of Efinopegdutide in Healthy Overweight/Obese Adults
NCT03606057Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2018
- Primary completion
- Feb 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity and Overweight comparing JNJ-64565111 Arm with Placebo/Control Arm (2 arms). Primary endpoints: Placebo-Corrected Change from Baseline in QT Interval Corrected for Individual Heart Rate (QTcI) at Day 26, Change from Time-Matched Baseline in QTc Interval and 3 more. Started Jul 2018; status: completed.
02
Drugs
efinopegdutide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT03606057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03606057.